Natalizumab is an α4-integrin antagonist, the first in its class for the treatment of multiple sclerosis (MS). Although multiple mechanisms have been proposed for the efficacy of natalizumab in MS, ...
Most patients with relapsing-remitting multiple sclerosis (RRMS) who are stable on natalizumab (Tysabri, Biogen) administered once every 4 weeks (Q4W) may be able to safely switch to a once every 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results